Mindray(SZ:300760) Southwest Securities·2024-05-06 01:33Investment Rating - The report maintains a "Buy" rating for Mindray Medical (300760) [1] Core Views - The company's performance in 2023 met expectations, with a total revenue of 34.93 billion yuan, representing a 15% increase, and a net profit of 11.58 billion yuan, up 20.6% [2][3] - The first quarter of 2024 showed a revenue of 9.37 billion yuan, a 12.1% increase, and a net profit of 3.16 billion yuan, up 22.9% [2] - The company has increased its dividend payout to approximately 7.03 billion yuan, a 28.9% year-on-year growth, with a payout ratio of 60.7% [2] Summary by Sections Financial Performance - 2023 total revenue was 34.93 billion yuan, with a net profit of 11.58 billion yuan, and a net profit margin of 33.2%, up 1.5 percentage points [2][3] - Quarterly revenues for 2023 were 8.36 billion, 10.11 billion, 8.83 billion, and 7.63 billion yuan, with respective net profits of 2.57 billion, 3.87 billion, 3.39 billion, and 1.75 billion yuan [2] - The gross margin for 2023 was 66.2%, with a continuous improvement in profitability [2] Business Segments - The life information and support segment generated 15.23 billion yuan in revenue, a 13.8% increase, driven by new medical infrastructure projects [3] - The in-vitro diagnostics segment saw revenue of 12.42 billion yuan, up 21.1%, with a strong recovery in domestic routine medical activities [3] - The medical imaging segment reported 7.03 billion yuan in revenue, an 8.8% increase, despite some delays in procurement activities due to regulatory impacts [3] Regional Performance - Domestic market revenue reached 21.38 billion yuan, a 14.5% increase, while international market revenue was 13.55 billion yuan, up 15.8% [3] Research and Development - R&D expenses for 2023 were 3.43 billion yuan, reflecting the company's commitment to product innovation, particularly in high-end fields [3] - The company plans to launch over 20 new projects in the chemical luminescence segment in 2024 [3] Profit Forecast - The forecast for net profit from 2024 to 2026 is 13.96 billion, 16.80 billion, and 20.21 billion yuan, with corresponding EPS of 11.52, 13.85, and 16.67 yuan [9][10]